Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has completed patient enrollment in a Phase 1-2 dose-escalation clinical trial of MDV3100, its novel androgen receptor antagonist, in castration-resistant prostate cancer patients, and that it will seek approval from the U.S. Food and Drug Administration (FDA) to advance to Phase 3 clinical trials next year.

The open-label, U.S. Phase 1-2 study evaluated prostate cancer patients who had failed standard hormonal therapies, including men who had also failed standard chemotherapy regimens. A total of 140 men were enrolled in the trial, which evaluated doses between 30 and 600 mg/day. Patients are being followed and may remain on treatment for as long as they continue to tolerate the drug and their disease does not progress.

Preliminary results of this trial, covering 73 treated patients in the 60, 150 and 240 mg/day dose groups, were presented in October at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The data showed encouraging and durable anti-tumor activity as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes and time on treatment. These data also suggested a dose-response trend, with a higher percentage of patients in the 240 mg/day dose group experiencing 90 percent reduction in PSA levels, radiographic partial responses and conversions to favorable CTC counts of less than five post-treatment.

The Company expects to move into Phase 3 trials with either the 240 or the 360 mg/day dose, both of which have been generally well tolerated. The 480 mg/day dose did not have acceptable tolerability due to side effects, primarily fatigue. Efficacy data from the 360 mg/day dose group are under analysis and wil
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Physicians and ... in the biopharmaceutical market. Patients are better informed ... selecting and switching therapies. This shift in power ... marketers, efforts toward patient-focused marketing. As ... marketers have learned it,s important to educate, communicate ...
(Date:7/31/2015)... , July 31, 2015  In today,s ever-changing marketplace, ... are increasingly mobile, increasingly connected, and increasingly impatient with ... of customer interaction channels and tools is driving call ... media. According to research by benchmarking ... counter (OTC) segment in a call center study realize ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... Randall as non-executive directors, LONDON, July 1 ... changes to its Board of Directors as,part of the ... appointed Annette Clancy and Jerry Randall,as non-executive directors and ... Annette Clancy is joining the Board in her ...
... To Launch,Collaborative Initiative, NEW YORK, July 1 ... cures for pediatric brain tumors and cancer, the ... phase of a tissue,bank consortium designed to jump-start ... for these types of cancer, where survival rates ...
Cached Medicine Technology:Silence Therapeutics Announces Board Changes 2Silence Therapeutics Announces Board Changes 3Silence Therapeutics Announces Board Changes 4Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 2Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 3
(Date:8/1/2015)... ... , ... On Tuesday, July 28th, Symantec released a security industry whitepaper ... the attack on Anthem Inc. which resulted in one of the largest data breaches ... spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO of ...
(Date:8/1/2015)... Atlanta, GA (PRWEB) , ... August 01, 2015 , ... ... iPhone app that is free to download on the Apple AppStore. , The ... energy levels, even mood, thus acting as a tool to view personal health and ...
(Date:8/1/2015)... ... , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has ... business donation to kick off the campaign for healing and Well-Being. , BeverlyD has ... complete line of raw, organic hair care products, as well as her book, Hair ...
(Date:8/1/2015)... ... , ... “ reTXT ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... and delete any message including ones already sent. , While text messaging has more ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... , August is National Immunization Awareness ... 3 Department of Health Secretary Everette James today stressed ... Month. , , "Recommended vaccinations begin soon ... your family are up-to-date on these immunizations is critical to ...
... odds for chronic illness, review finds , MONDAY, Aug. 3 ... greater risk of developing kidney disease later in life, according ... found that people who were less than 5.5 pounds at ... disease than those with normal birth weight. The findings appear ...
... over their usefulness , MONDAY, Aug. 3 (HealthDay News) -- ... masks to ward off the flu, and the results of ... , Researchers in Hong Kong found that wearing a surgical ... transmission rates for the seasonal flu down, at least among ...
... , TEMPLE, Texas, Aug. 3 Scott ... at a national conference in Washington, DC titled "How Do They Do ... the only Texas health care system and one of 10 health systems ... , , The event was jointly hosted by The ...
... , , BEDFORD, Mass., Aug. 3 ... manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to ... June 27, 2009. , , Highlights of the quarter include: ... Revenues of $403.1 million. , Third quarter 2009 net income ...
... , , , , ... Uroplasty, Inc. (NYSE Amex: UPI ), a medical device ... dysfunctions, today reported financial results for the first fiscal quarter ended June ... the strategy we communicated at the beginning of the fiscal year of ...
Cached Medicine News:Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 3Health News:Low Birth Weight Might Raise Adult Kidney Disease Risk 2Health News:Surgical Masks Help Ward Off Flu, Maybe 2Health News:Surgical Masks Help Ward Off Flu, Maybe 3Health News:Surgical Masks Help Ward Off Flu, Maybe 4Health News:Scott & White Leadership Invited to National Forum on High Quality, Low-Cost Health Care 2Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 2Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 3Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 4Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 5Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 6Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 7Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 8Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 9Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 10Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 11Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 12Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 13Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 14Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 15Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 16Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 17Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 18Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 19Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 20Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 21Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 22Health News:Hologic Announces Third Quarter Fiscal 2009 Operating Results 23Health News:Uroplasty Reports First Fiscal Quarter Results 2Health News:Uroplasty Reports First Fiscal Quarter Results 3Health News:Uroplasty Reports First Fiscal Quarter Results 4Health News:Uroplasty Reports First Fiscal Quarter Results 5Health News:Uroplasty Reports First Fiscal Quarter Results 6Health News:Uroplasty Reports First Fiscal Quarter Results 7
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled 45 degree shafts with 10.5 mm tying platform. 1 mm of tip is crisscross serrated. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled shafts with 10 mm tying platform. True round knurled handle in the closed position with polished finish. Overall length 4.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 5 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Medicine Products: